SCHEMBL30294688

SCHEMBL30294688

Cc1cc(F)ccc1Nc1cc(F)c(Br)cc1C(=O)O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.44
CLCN2 P51788 1/20 0.44
DHODH Q02127 2/20 0.44
P2RY4 P51582 1/20 0.44
KCNK2 O95069 1/20 0.44
KCNK10 P57789 1/20 0.44
ALDH1A1 P00352 4/20 0.43
MAPT P10636 3/20 0.42
GAA P10253 1/20 0.42
MKNK2 Q9HBH9 1/20 0.41
MAPK13 O15264 1/20 0.41
MAPK12 P53778 1/20 0.41
MAPK11 Q15759 1/20 0.41
MAPK14 Q16539 1/20 0.41
FABP3 P05413 1/20 0.41
FABP4 P15090 1/20 0.41
FTO Q9C0B1 1/20 0.40
MPO P05164 1/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22852820 1.00 IDO1 (0.44) IDO1CLCN2DHODHP2RY4KCNK2
SCHEMBL30294377 0.89 IDO1 (0.48) IDO1CLCN2DHODHP2RY4ALDH1A1
SCHEMBL22853121 0.89 IDO1 (0.48) IDO1CLCN2DHODHP2RY4ALDH1A1
SCHEMBL4860619 0.87 IDO1 (0.60) IDO1KCNK2KCNK10MEN1KMT2A
SCHEMBL22852769 0.87 ALDH1A1 (0.42) ALDH1A1MAPTGAAMAPK13MAPK12
SCHEMBL22853346 0.85 IDO1 (0.50) IDO1CLCN2DHODHP2RY4ALDH1A1
SCHEMBL30294440 0.85 IDO1 (0.50) IDO1CLCN2DHODHP2RY4ALDH1A1
SCHEMBL22853383 0.84 P2RY4 (0.56) IDO1CLCN2DHODHP2RY4KCNK2
SCHEMBL30294653 0.84 P2RY4 (0.56) IDO1CLCN2DHODHP2RY4KCNK2
SCHEMBL22853082 0.84 CLCN2 (0.53) IDO1CLCN2DHODHP2RY4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230103791-A1 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-04-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230103791-A1 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS SCN8A, SCN1A, SCN1B IDO1 3449/4885CLCN2 192/4885DHODH 1951/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.